Pub Date : 2025-06-19eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10560
Thomas Winkens, Pauline Schweitzer, Olga Perkas, Christian Kühnel, Ferdinand Ndum, Marta Pomraenke, Julia Greiser, Martin Freesmeyer
In-ovo imaging using ostrich eggs has been described as an alternative to animal testing using rodents. This approach is not considered an animal experiment and it does not require small-animal imaging devices as ostrich eggs provide good image quality on regular CT, MRI or PET used in humans. The aims of this study were 1) to describe methods of radiopharmaceutical injection, 2) to explore normal biodistribution of F-18-FDG during a 60-min list-mode-PET/CT examination and 3) to compare biodistribution in-ovo to existing literature considering chicken and rodents. Vessel access was successful in 54/78 ostrich eggs. Highest FDG-uptake was observed in epiphyseal plates (0.36 ± 0.06 IA%/g; range 0.29-0.48 IA%/g) and brain (0.25 ± 0.05 IA%/g; range 0.21-0.36 IA%/g). In-vivo activity distribution on PET and ex-vivo activity distribution (well counter) showed comparable results (Spearman's Rho range 0.795-0.882). No significant differences were observed regarding previous isoflurane exposure. Normal biodistribution of F-18-FDG in ostrich embryos using a standard PET/CT system for humans was mainly found as expected with highest uptake in epiphyseal plates and brain which is comparable to results on rodents and chicken embryos. Isoflurane anesthesia did not reveal significant differences regarding organ uptake. The results of this normal distribution study allow for interpretation of future disease models (inflammation, tumor) in ostrich embryos using F-18-FDG as radiopharmaceutical.
{"title":"In-ovo imaging using ostrich eggs: biodistribution of F-18-FDG in ostrich embryos.","authors":"Thomas Winkens, Pauline Schweitzer, Olga Perkas, Christian Kühnel, Ferdinand Ndum, Marta Pomraenke, Julia Greiser, Martin Freesmeyer","doi":"10.3389/ebm.2025.10560","DOIUrl":"10.3389/ebm.2025.10560","url":null,"abstract":"<p><p>In-ovo imaging using ostrich eggs has been described as an alternative to animal testing using rodents. This approach is not considered an animal experiment and it does not require small-animal imaging devices as ostrich eggs provide good image quality on regular CT, MRI or PET used in humans. The aims of this study were 1) to describe methods of radiopharmaceutical injection, 2) to explore normal biodistribution of F-18-FDG during a 60-min list-mode-PET/CT examination and 3) to compare biodistribution in-ovo to existing literature considering chicken and rodents. Vessel access was successful in 54/78 ostrich eggs. Highest FDG-uptake was observed in epiphyseal plates (0.36 ± 0.06 IA%/g; range 0.29-0.48 IA%/g) and brain (0.25 ± 0.05 IA%/g; range 0.21-0.36 IA%/g). <i>In-vivo</i> activity distribution on PET and <i>ex-vivo</i> activity distribution (well counter) showed comparable results (Spearman's Rho range 0.795-0.882). No significant differences were observed regarding previous isoflurane exposure. Normal biodistribution of F-18-FDG in ostrich embryos using a standard PET/CT system for humans was mainly found as expected with highest uptake in epiphyseal plates and brain which is comparable to results on rodents and chicken embryos. Isoflurane anesthesia did not reveal significant differences regarding organ uptake. The results of this normal distribution study allow for interpretation of future disease models (inflammation, tumor) in ostrich embryos using F-18-FDG as radiopharmaceutical.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10560"},"PeriodicalIF":2.8,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-17eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10517
Xiaojing Du, Xiaohui Li, Sheng Yue, Yuzhen Sun, Mengzhen Zhao, Lingshan Zhou, Xingwei Wang, Yapan Yang
This study explored the association between inflammatory biomarkers-C-reactive protein to albumin ratio (CAR), platelet to lymphocyte ratio (PLR), and neutrophil to lymphocyte ratio (NLR)-and the prognosis of patients with cardiogenic cerebral embolism (CCE). We retrospectively analyzed data from 80 CCE patients diagnosed between June 2020 and June 2024, categorizing them into favorable and unfavorable prognosis groups based on outcomes such as death, recurrence, and disability. The CAR, PLR, and NLR values were calculated from routine blood tests, and statistical analyses, including Spearman correlation, multivariate logistic regression, and ROC curve analysis, were performed to examine their prognostic significance. Results showed that the unfavorable prognosis group had significantly higher CAR, PLR, and NLR values compared to the favorable group (P < 0.05). Spearman correlation analysis revealed positive associations between these biomarkers and prognosis (r = 0.319 for CAR, 0.238 for PLR, 0.251 for NLR, all P < 0.05). Multivariate analysis identified CAR and NLR as independent risk factors for unfavorable prognosis (OR = 1.034 for CAR, OR = 3.887 for NLR). ROC analysis determined optimal cutoff values for CAR (>0.74), PLR (>160.00), and NLR (>3.53) to predict unfavorable prognosis with AUCs of 0.796, 0.694, and 0.705, respectively. The combined biomarker test yielded an AUC of 0.899. Kaplan-Meier survival analysis indicated significantly lower survival rates for patients with higher levels of CAR, PLR, and NLR (P < 0.05). In conclusion, elevated CAR, PLR, and NLR are reliable indicators of a poor prognosis in CCE patients.
{"title":"Correlation study of CAR, PLR, NLR with the prognosis of cardiogenic cerebral embolism patients.","authors":"Xiaojing Du, Xiaohui Li, Sheng Yue, Yuzhen Sun, Mengzhen Zhao, Lingshan Zhou, Xingwei Wang, Yapan Yang","doi":"10.3389/ebm.2025.10517","DOIUrl":"10.3389/ebm.2025.10517","url":null,"abstract":"<p><p>This study explored the association between inflammatory biomarkers-C-reactive protein to albumin ratio (CAR), platelet to lymphocyte ratio (PLR), and neutrophil to lymphocyte ratio (NLR)-and the prognosis of patients with cardiogenic cerebral embolism (CCE). We retrospectively analyzed data from 80 CCE patients diagnosed between June 2020 and June 2024, categorizing them into favorable and unfavorable prognosis groups based on outcomes such as death, recurrence, and disability. The CAR, PLR, and NLR values were calculated from routine blood tests, and statistical analyses, including Spearman correlation, multivariate logistic regression, and ROC curve analysis, were performed to examine their prognostic significance. Results showed that the unfavorable prognosis group had significantly higher CAR, PLR, and NLR values compared to the favorable group (P < 0.05). Spearman correlation analysis revealed positive associations between these biomarkers and prognosis (r = 0.319 for CAR, 0.238 for PLR, 0.251 for NLR, all P < 0.05). Multivariate analysis identified CAR and NLR as independent risk factors for unfavorable prognosis (OR = 1.034 for CAR, OR = 3.887 for NLR). ROC analysis determined optimal cutoff values for CAR (>0.74), PLR (>160.00), and NLR (>3.53) to predict unfavorable prognosis with AUCs of 0.796, 0.694, and 0.705, respectively. The combined biomarker test yielded an AUC of 0.899. Kaplan-Meier survival analysis indicated significantly lower survival rates for patients with higher levels of CAR, PLR, and NLR (P < 0.05). In conclusion, elevated CAR, PLR, and NLR are reliable indicators of a poor prognosis in CCE patients.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10517"},"PeriodicalIF":2.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12208937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144539731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-13eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10608
Leah E Latham, Qiang Gu, Shuliang Liu, Cheng Wang, Fang Liu
Cannabidiol (CBD) has been used for different purposes by different populations in recent years. When consumed by pregnant women, CBD can pass through the placenta and enter the fetal blood stream. There is concern over adverse effects of fetal exposure to CBD and its major metabolites (7-OH-CBD and 7-COOH-CBD). In the present study, human neural stem cells (NSCs) were treated with CBD and its metabolites at different concentrations for various durations to understand how the drug may affect fetal brain development. NSCs were also treated with delta-9 tetrahydrocannabinol (THC) for comparison purposes. CBD, 7-OH-CBD and 7-COOH-CBD dose-dependently reduced NSC viability. CBD and 7-OH-CBD reduced NSC number at the G1 phase. A 24 h exposure did not cause significant change in NSC proliferation. At concentrations comparable to those detected in human blood, longer exposures to CBD, 7-OH-CBD and 7-COOH-CBD caused more obvious cell death. After NSCs differentiation, CBD treatment reduced GFAP and cannabinoid receptor 2 (CB2) expression. THC treatment reduced the GFAP expression, but the change in CB2 expression did not reach statistical significance. The expression of cannabinoid receptor 1 (CB1) and beta-tubulin III were not significantly altered by drug exposures. The study demonstrated that clinically relevant concentrations of CBD, 7-OH-CBD and 7-COOH-CBD affect basic physiological features of human NSCs. After NSC differentiation, the reduced expression of CB2 receptors and GFAP on differentiated cells further indicated the vulnerability of developing central nervous system to CBD and THC. These data will help to contextualize in vivo neurodevelopmental studies that may not accurately model human metabolite profiles of CBD.
{"title":"The effects of cannabidiol and its main metabolites on human neural stem cells.","authors":"Leah E Latham, Qiang Gu, Shuliang Liu, Cheng Wang, Fang Liu","doi":"10.3389/ebm.2025.10608","DOIUrl":"10.3389/ebm.2025.10608","url":null,"abstract":"<p><p>Cannabidiol (CBD) has been used for different purposes by different populations in recent years. When consumed by pregnant women, CBD can pass through the placenta and enter the fetal blood stream. There is concern over adverse effects of fetal exposure to CBD and its major metabolites (7-OH-CBD and 7-COOH-CBD). In the present study, human neural stem cells (NSCs) were treated with CBD and its metabolites at different concentrations for various durations to understand how the drug may affect fetal brain development. NSCs were also treated with delta-9 tetrahydrocannabinol (THC) for comparison purposes. CBD, 7-OH-CBD and 7-COOH-CBD dose-dependently reduced NSC viability. CBD and 7-OH-CBD reduced NSC number at the G1 phase. A 24 h exposure did not cause significant change in NSC proliferation. At concentrations comparable to those detected in human blood, longer exposures to CBD, 7-OH-CBD and 7-COOH-CBD caused more obvious cell death. After NSCs differentiation, CBD treatment reduced GFAP and cannabinoid receptor 2 (CB2) expression. THC treatment reduced the GFAP expression, but the change in CB2 expression did not reach statistical significance. The expression of cannabinoid receptor 1 (CB1) and beta-tubulin III were not significantly altered by drug exposures. The study demonstrated that clinically relevant concentrations of CBD, 7-OH-CBD and 7-COOH-CBD affect basic physiological features of human NSCs. After NSC differentiation, the reduced expression of CB2 receptors and GFAP on differentiated cells further indicated the vulnerability of developing central nervous system to CBD and THC. These data will help to contextualize <i>in vivo</i> neurodevelopmental studies that may not accurately model human metabolite profiles of CBD.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10608"},"PeriodicalIF":2.8,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-13eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10606
Cheng Wang, Leah E Latham, Shuliang Liu, John Talpos, Tucker A Patterson, Joseph P Hanig, Fang Liu
Safety concerns about general anesthetics (GA), such as desflurane (a commonly used gaseous anesthetic agent), arose from studies documenting neural cell death and behavioral changes after early-life exposure to anesthetics and compounds with related modes of action. Neural stem cells (NSCs) can recapitulate most critical events during central nervous system (CNS) development in vivo and, therefore, represent a valuable in vitro model for evaluating potential desflurane-induced developmental neurotoxicity. In this study, NSCs harvested from the hippocampus of a gestational day 80 monkey brain were applied to explore the temporal relationships between desflurane exposures and neural stem cell health, proliferation, differentiation, and viability. At clinically relevant doses (5.7%), desflurane exposure did not result in significant changes in NSC viability [lactate dehydrogenase (LDH) release] and NSC proliferation profile/rate by Cell Cycle Assay, in both short term (3 h) and prolonged (24 h) exposure groups. However, when monkey NSCs were guided to differentiate into neural cells (including neurons, astrocytes, and oligodendrocytes), and then exposed to desflurane (5.7%), no significant changes were detected in LDH release after a 3-h exposure, but a significant elevation in LDH release into the culture medium was observed after a 24-h exposure. Desflurane (24 h)-induced neural damage was further supported by increased expression levels of multiple cytokines, e.g., G-CSF, IL-12, IL-9, IL-10, and TNF-α compared with the controls. Additionally, our immunocytochemistry and flow cytometry data demonstrated a remarkable attenuation of differentiated neurons as evidenced by significantly decreased numbers of polysialic acid neural cell adhesion molecule (PSA-NCAM)-positive cells in the desflurane-exposed (prolonged) cultures. Our data suggests that at the clinically relevant concentration, desflurane did not induce NSC damage/death, but impaired the differentiated neuronal cells after prolonged exposure. Collectively, PSA-NCAM could be essential for neuronal viability. Desflurane-induced neurotoxicity was primarily associated with the loss of differentiated neurons. Changes in the neuronal specific marker, PSA-NCAM, may help understand the underlying mechanisms associated with anesthetic-induced neuronal damage. These findings should be helpful/useful for the understanding of the diverse effects of desflurane exposure on the developing brain and could be used to optimize the usage of these agents in the pediatric setting.
{"title":"Assessing potential desflurane-induced neurotoxicity using nonhuman primate neural stem cell models.","authors":"Cheng Wang, Leah E Latham, Shuliang Liu, John Talpos, Tucker A Patterson, Joseph P Hanig, Fang Liu","doi":"10.3389/ebm.2025.10606","DOIUrl":"10.3389/ebm.2025.10606","url":null,"abstract":"<p><p>Safety concerns about general anesthetics (GA), such as desflurane (a commonly used gaseous anesthetic agent), arose from studies documenting neural cell death and behavioral changes after early-life exposure to anesthetics and compounds with related modes of action. Neural stem cells (NSCs) can recapitulate most critical events during central nervous system (CNS) development <i>in vivo</i> and, therefore, represent a valuable <i>in vitro</i> model for evaluating potential desflurane-induced developmental neurotoxicity. In this study, NSCs harvested from the hippocampus of a gestational day 80 monkey brain were applied to explore the temporal relationships between desflurane exposures and neural stem cell health, proliferation, differentiation, and viability. At clinically relevant doses (5.7%), desflurane exposure did not result in significant changes in NSC viability [lactate dehydrogenase (LDH) release] and NSC proliferation profile/rate by Cell Cycle Assay, in both short term (3 h) and prolonged (24 h) exposure groups. However, when monkey NSCs were guided to differentiate into neural cells (including neurons, astrocytes, and oligodendrocytes), and then exposed to desflurane (5.7%), no significant changes were detected in LDH release after a 3-h exposure, but a significant elevation in LDH release into the culture medium was observed after a 24-h exposure. Desflurane (24 h)-induced neural damage was further supported by increased expression levels of multiple cytokines, e.g., G-CSF, IL-12, IL-9, IL-10, and TNF-α compared with the controls. Additionally, our immunocytochemistry and flow cytometry data demonstrated a remarkable attenuation of differentiated neurons as evidenced by significantly decreased numbers of polysialic acid neural cell adhesion molecule (PSA-NCAM)-positive cells in the desflurane-exposed (prolonged) cultures. Our data suggests that at the clinically relevant concentration, desflurane did not induce NSC damage/death, but impaired the differentiated neuronal cells after prolonged exposure. Collectively, PSA-NCAM could be essential for neuronal viability. Desflurane-induced neurotoxicity was primarily associated with the loss of differentiated neurons. Changes in the neuronal specific marker, PSA-NCAM, may help understand the underlying mechanisms associated with anesthetic-induced neuronal damage. These findings should be helpful/useful for the understanding of the diverse effects of desflurane exposure on the developing brain and could be used to optimize the usage of these agents in the pediatric setting.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10606"},"PeriodicalIF":2.8,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-10eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10550
Abigail Martin, Ian Coulter, Reginald Cox, Douglas F Covey, Slobodan M Todorovic, Tamara Timic Stamenic
Since the discovery of their anesthetic effects, some neuroactive steroids have been used as general anesthetics. However, their effects on thalamocortical oscillations and potential sex differences that are associated with their hypnotic/sedative effects are not well studied. Here, we investigated spectral characteristics and sex differences in hypnotic effect of two common neuroactive steroids: Allopregnanolone (AlloP) and its synthetic analog Alphaxalone (Alpx) in wild type mice using behavioral testing (loss of righting reflex - LORR) and in vivo electrophysiology. Our data revealed sex-differences in LORR duration with 100 mg/kg intraperitoneally injected AlloP and Alpx confirming that females are more sensitive to neuroactive steroid-induced hypnosis. Spectral analysis, thalamocortical and corticocortical phase synchronization showed notable differences between two neuroactive steroids. AlloP induced a profound reduction in local field potential (LFP) and electroencephalogram (EEG) after LORR with higher LFP/EEG suppression in females during first 60 min after injection. Also, we observed a decrease in thalamocortical synchronization in lower (delta, theta, alpha) and increase in higher low gamma frequency in AlloP group; similar effects were observed in Alpx treated animals with no change in delta thalamocortical phase locking values. Synchronization between right and left cortex was reduced in all frequencies except low gamma in AlloP-treated group. Similarly, Alpx induced reduction in corticocortical synchronization for theta, alpha and beta frequencies. We conclude that AlloP and Alpx have distinct electrophysiological signatures in thalamocortical circuitry that may underly their sedative/hypnotic effects.
{"title":"Comparative electrophysiological study of neuroactive steroid-induced hypnosis in mice: sex and drug-specific differences.","authors":"Abigail Martin, Ian Coulter, Reginald Cox, Douglas F Covey, Slobodan M Todorovic, Tamara Timic Stamenic","doi":"10.3389/ebm.2025.10550","DOIUrl":"10.3389/ebm.2025.10550","url":null,"abstract":"<p><p>Since the discovery of their anesthetic effects, some neuroactive steroids have been used as general anesthetics. However, their effects on thalamocortical oscillations and potential sex differences that are associated with their hypnotic/sedative effects are not well studied. Here, we investigated spectral characteristics and sex differences in hypnotic effect of two common neuroactive steroids: Allopregnanolone (AlloP) and its synthetic analog Alphaxalone (Alpx) in wild type mice using behavioral testing (loss of righting reflex - LORR) and <i>in vivo</i> electrophysiology. Our data revealed sex-differences in LORR duration with 100 mg/kg intraperitoneally injected AlloP and Alpx confirming that females are more sensitive to neuroactive steroid-induced hypnosis. Spectral analysis, thalamocortical and corticocortical phase synchronization showed notable differences between two neuroactive steroids. AlloP induced a profound reduction in local field potential (LFP) and electroencephalogram (EEG) after LORR with higher LFP/EEG suppression in females during first 60 min after injection. Also, we observed a decrease in thalamocortical synchronization in lower (delta, theta, alpha) and increase in higher low gamma frequency in AlloP group; similar effects were observed in Alpx treated animals with no change in delta thalamocortical phase locking values. Synchronization between right and left cortex was reduced in all frequencies except low gamma in AlloP-treated group. Similarly, Alpx induced reduction in corticocortical synchronization for theta, alpha and beta frequencies. We conclude that AlloP and Alpx have distinct electrophysiological signatures in thalamocortical circuitry that may underly their sedative/hypnotic effects.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10550"},"PeriodicalIF":2.8,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144483686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-09eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10598
Abiel K Biney, Caroline R Schultz, Michael F Stone, Donna A Nguyen, Annie Wang, Marcio de Araujo Furtado, Lucille A Lumley
Acute exposure to a seizure-inducing dose of an organophosphorus nerve agent inhibits acetylcholinesterase, leading to pharmacoresistance if benzodiazepine treatment is delayed. Following soman-induced status epilepticus (SE) in rats, prolonged seizure is associated with severe and widespread neurodegeneration. We evaluated the aminothiol cystamine, the oxidized form of cysteamine, for neuroprotective potential against soman-induced SE and associated neurodegeneration. Cystamine has a myriad of effects including antioxidant properties, neuroprotective effects, and immunomodulation, among others, which is of interest in evaluating neuroprotective efficacy against cholinergic-induced neurodegeneration. Adult male rats implanted with telemetry transmitters for continuous EEG recording were exposed to soman and treated with the muscarinic antagonist atropine sulfate and the oxime asoxime dimethanesulfonate 1 min after exposure to increase survival. Midazolam was administered 30 min after seizure onset. Cystamine (10 or 50 mg/kg) or vehicle was administered 30 min after seizure onset and again 4 h after soman exposure. The initial seizure duration, the EEG power integral at 6 h after exposure, and the percentage of rats that developed spontaneous recurrent seizure were reduced in rats treated with cystamine, compared to those that received only midazolam. In addition, cystamine reduced neurodegeneration in seizure-sensitive brain regions following soman exposure, compared to midazolam. Our findings highlight the potential for aminothiols to serve as adjunctive therapy to midazolam in treating cholinergic-induced toxicity and suggest broader applications of aminothiols in neuroprotection and neurological disorders.
{"title":"Cystamine reduces neurodegeneration and epileptogenesis following soman-induced status epilepticus in rats.","authors":"Abiel K Biney, Caroline R Schultz, Michael F Stone, Donna A Nguyen, Annie Wang, Marcio de Araujo Furtado, Lucille A Lumley","doi":"10.3389/ebm.2025.10598","DOIUrl":"10.3389/ebm.2025.10598","url":null,"abstract":"<p><p>Acute exposure to a seizure-inducing dose of an organophosphorus nerve agent inhibits acetylcholinesterase, leading to pharmacoresistance if benzodiazepine treatment is delayed. Following soman-induced status epilepticus (SE) in rats, prolonged seizure is associated with severe and widespread neurodegeneration. We evaluated the aminothiol cystamine, the oxidized form of cysteamine, for neuroprotective potential against soman-induced SE and associated neurodegeneration. Cystamine has a myriad of effects including antioxidant properties, neuroprotective effects, and immunomodulation, among others, which is of interest in evaluating neuroprotective efficacy against cholinergic-induced neurodegeneration. Adult male rats implanted with telemetry transmitters for continuous EEG recording were exposed to soman and treated with the muscarinic antagonist atropine sulfate and the oxime asoxime dimethanesulfonate 1 min after exposure to increase survival. Midazolam was administered 30 min after seizure onset. Cystamine (10 or 50 mg/kg) or vehicle was administered 30 min after seizure onset and again 4 h after soman exposure. The initial seizure duration, the EEG power integral at 6 h after exposure, and the percentage of rats that developed spontaneous recurrent seizure were reduced in rats treated with cystamine, compared to those that received only midazolam. In addition, cystamine reduced neurodegeneration in seizure-sensitive brain regions following soman exposure, compared to midazolam. Our findings highlight the potential for aminothiols to serve as adjunctive therapy to midazolam in treating cholinergic-induced toxicity and suggest broader applications of aminothiols in neuroprotection and neurological disorders.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10598"},"PeriodicalIF":2.8,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-09eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10330
Haoyang Zheng, Duo Zhang, Wei Xiang, Yong Gan, Zesheng Peng, Yuyi Wu, Peng Fu
Dystonia, a challenging movement disorder, poses significant therapeutic challenges due to its resistance to treatment, resulting in both physical impairment and substantial mental distress, ultimately impacting overall quality of life. Cerebral palsy (CP) is a major non-genetic cause of secondary dystonia, characterized by diverse clinical presentations. This study aims to comprehensively evaluate the effectiveness of deep brain stimulation (DBS) as a therapeutic intervention for individuals with dystonic CP. We conducted a systematic analysis of studies assessing the safety and effectiveness of DBS, with a focus on its long-term outcomes [PROSPERO (Unique identifier: CRD42023399285)]. We examined factors that influence treatment response and proposed strategies to enhance patient quality of life. DBS, especially when targeting the basal ganglia or innovative targets, shows promise as a therapeutic approach for dystonic CP. While existing controlled studies confirm its safety and effectiveness, a thorough evaluation of long-term efficacy remains crucial. This research highlights the potential of DBS in improving the lives of individuals with dystonic CP, providing hope for further refinement, innovation, and broader clinical application of this therapeutic approach.
{"title":"Deep brain stimulation for dystonia treatment in cerebral palsy: efficacy exploration.","authors":"Haoyang Zheng, Duo Zhang, Wei Xiang, Yong Gan, Zesheng Peng, Yuyi Wu, Peng Fu","doi":"10.3389/ebm.2025.10330","DOIUrl":"10.3389/ebm.2025.10330","url":null,"abstract":"<p><p>Dystonia, a challenging movement disorder, poses significant therapeutic challenges due to its resistance to treatment, resulting in both physical impairment and substantial mental distress, ultimately impacting overall quality of life. Cerebral palsy (CP) is a major non-genetic cause of secondary dystonia, characterized by diverse clinical presentations. This study aims to comprehensively evaluate the effectiveness of deep brain stimulation (DBS) as a therapeutic intervention for individuals with dystonic CP. We conducted a systematic analysis of studies assessing the safety and effectiveness of DBS, with a focus on its long-term outcomes [PROSPERO (Unique identifier: CRD42023399285)]. We examined factors that influence treatment response and proposed strategies to enhance patient quality of life. DBS, especially when targeting the basal ganglia or innovative targets, shows promise as a therapeutic approach for dystonic CP. While existing controlled studies confirm its safety and effectiveness, a thorough evaluation of long-term efficacy remains crucial. This research highlights the potential of DBS in improving the lives of individuals with dystonic CP, providing hope for further refinement, innovation, and broader clinical application of this therapeutic approach.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10330"},"PeriodicalIF":2.8,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12183516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-06eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10350
Molly K Abban, Eunice Ampadubea Ayerakwa, Abiola Isawumi
The threat of antimicrobial resistance in Ghana is increasing with the recent emergence of KAPE pathogens (K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species) from the hospital environment. As opportunistic pathogens, KAPE leverage the formation of biofilms and swarms to survive stringent environmental conditions. As research continues to investigate approaches that bacteria employ to exacerbate infection, this study explored biofilm and swarm formation in MDR KAPE pathogens under polymyxin B stress emerging from Ghanaian hospitals. The antimicrobial susceptibility profile of KAPE pathogens to conventional antibiotics and polymyxin B was investigated via antibiotic disk diffusion and broth microdilution assays. Biofilm inhibition and eradication assays, swarm motility and a resazurin-based metabolic assay were used to profile bacterial phenotypic characteristics under polymyxin B stress. The strains exhibited resistance to the tested antibiotics with a high level of resistance to polymyxin B (PMB) (≥512 μg/mL). Additionally, the strains formed biofilms and bacterial swarms at 37°C. In the presence of PMB (≥512 μg/mL), KAPE pathogens formed swarms with no significant reduction in bacterial swarms at 1,048 μg/mL. Biofilm was observed for all strains with PMB neither inhibiting nor eradicating at high PMB (2048 μg/mL). Additionally, there were no significant differences in the phenotypic and antimicrobial susceptibility profiles of clinical and environmental KAPE pathogens from Ghanaian ICUs. Overall, the study established that clinical and environmental KAPE pathogens from Ghanaian ICUs exhibit adaptive phenotypic and resistance characteristics that could potentially enhance bacterial survival during host colonization and infection. This could undermine treatment strategies and pose public health challenges in Ghana.
{"title":"Biofilm and surface-motility profiles under polymyxin B stress in multidrug-resistant KAPE pathogens isolated from Ghanaian hospital ICUs.","authors":"Molly K Abban, Eunice Ampadubea Ayerakwa, Abiola Isawumi","doi":"10.3389/ebm.2025.10350","DOIUrl":"10.3389/ebm.2025.10350","url":null,"abstract":"<p><p>The threat of antimicrobial resistance in Ghana is increasing with the recent emergence of KAPE pathogens (<i>K. pneumoniae</i>, <i>A. baumannii</i>, <i>P. aeruginosa</i> and <i>Enterobacter</i> species) from the hospital environment. As opportunistic pathogens, KAPE leverage the formation of biofilms and swarms to survive stringent environmental conditions. As research continues to investigate approaches that bacteria employ to exacerbate infection, this study explored biofilm and swarm formation in MDR KAPE pathogens under polymyxin B stress emerging from Ghanaian hospitals. The antimicrobial susceptibility profile of KAPE pathogens to conventional antibiotics and polymyxin B was investigated via antibiotic disk diffusion and broth microdilution assays. Biofilm inhibition and eradication assays, swarm motility and a resazurin-based metabolic assay were used to profile bacterial phenotypic characteristics under polymyxin B stress. The strains exhibited resistance to the tested antibiotics with a high level of resistance to polymyxin B (PMB) (≥512 μg/mL). Additionally, the strains formed biofilms and bacterial swarms at 37°C. In the presence of PMB (≥512 μg/mL), KAPE pathogens formed swarms with no significant reduction in bacterial swarms at 1,048 μg/mL. Biofilm was observed for all strains with PMB neither inhibiting nor eradicating at high PMB (2048 μg/mL). Additionally, there were no significant differences in the phenotypic and antimicrobial susceptibility profiles of clinical and environmental KAPE pathogens from Ghanaian ICUs. Overall, the study established that clinical and environmental KAPE pathogens from Ghanaian ICUs exhibit adaptive phenotypic and resistance characteristics that could potentially enhance bacterial survival during host colonization and infection. This could undermine treatment strategies and pose public health challenges in Ghana.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10350"},"PeriodicalIF":2.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12180397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144368739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-03eCollection Date: 2025-01-01DOI: 10.3389/ebm.2025.10575
Abigail L Pfaff, Sulev Kõks
An individual's genetics contributes to their risk of developing amyotrophic lateral sclerosis (ALS); however, there is still a large proportion of the heritability of ALS to be understood. Part of this missing heritability may lie in complex variants, such as the long interspersed element 1 (L1) retrotransposon, which have yet to be evaluated. The majority of L1 insertions in the human genome are no longer able to retrotranspose, but to date 279 retrotransposition-competent (RC) L1s have been reported. Many RC-L1s are polymorphic for their presence/absence; therefore, each individual will have a different number and complement of RC-L1s. These elements have been hypothesized to be involved in disease processes by multiple mechanisms such as somatic mutation by retrotransposition, the triggering of neuroinflammation and DNA damage. We hypothesize that L1s may influence disease development either through their effects on endogenous genes or through the properties that enable them to retrotranspose. Whole genome sequencing data from the New York Genome Center ALS consortium were used to characterize L1 variation identifying 2,803 polymorphic L1 elements and association analysis was performed in European individuals (ALS/ALS with other neurological disorder (ALSND) n = 2,653, controls n = 320). There were no individual L1 elements associated with disease, but we did identify a significant increase in the number of RC-L1s in ALS/ALSND genomes (p = 0.01) and the presence of ≥46 RC-L1s showed the most significant association (OR = 1.09 (1.02-1.16), p = 0.01) with disease. Analysis of individual L1s and their association with age at onset and survival identified one L1 whose presence was significantly associated with a lower age at onset (52.7 years) compared to homozygous absent individuals (59.2 years) (padj = 0.009). Our study has identified novel genetic factors for both disease risk and age at onset in ALS providing further evidence for the role of L1 retrotransposons in neurodegenerative diseases.
{"title":"Retrotransposition-competent L1s are increased in the genomes of individuals with amyotrophic lateral sclerosis.","authors":"Abigail L Pfaff, Sulev Kõks","doi":"10.3389/ebm.2025.10575","DOIUrl":"10.3389/ebm.2025.10575","url":null,"abstract":"<p><p>An individual's genetics contributes to their risk of developing amyotrophic lateral sclerosis (ALS); however, there is still a large proportion of the heritability of ALS to be understood. Part of this missing heritability may lie in complex variants, such as the long interspersed element 1 (L1) retrotransposon, which have yet to be evaluated. The majority of L1 insertions in the human genome are no longer able to retrotranspose, but to date 279 retrotransposition-competent (RC) L1s have been reported. Many RC-L1s are polymorphic for their presence/absence; therefore, each individual will have a different number and complement of RC-L1s. These elements have been hypothesized to be involved in disease processes by multiple mechanisms such as somatic mutation by retrotransposition, the triggering of neuroinflammation and DNA damage. We hypothesize that L1s may influence disease development either through their effects on endogenous genes or through the properties that enable them to retrotranspose. Whole genome sequencing data from the New York Genome Center ALS consortium were used to characterize L1 variation identifying 2,803 polymorphic L1 elements and association analysis was performed in European individuals (ALS/ALS with other neurological disorder (ALSND) n = 2,653, controls n = 320). There were no individual L1 elements associated with disease, but we did identify a significant increase in the number of RC-L1s in ALS/ALSND genomes (p = 0.01) and the presence of ≥46 RC-L1s showed the most significant association (OR = 1.09 (1.02-1.16), p = 0.01) with disease. Analysis of individual L1s and their association with age at onset and survival identified one L1 whose presence was significantly associated with a lower age at onset (52.7 years) compared to homozygous absent individuals (59.2 years) (padj = 0.009). Our study has identified novel genetic factors for both disease risk and age at onset in ALS providing further evidence for the role of L1 retrotransposons in neurodegenerative diseases.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10575"},"PeriodicalIF":2.8,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12172249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144316255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The relationship between drinking and sarcopenia remains controversial. The aim of the present study was to investigate the association of alcohol drinking with sarcopenia in the older adults. A prospective study with 5244 Chinese community-dwelling older adults aged ≥65 years was performed. Sarcopenia was assessed by appendicular skeletal muscle mass index, grip strength, and gait speed. A quantitative questionnaire was used to obtain the information of alcohol drinking. After 4-year follow-up, our study showed that drinkers had lower incidence of sarcopenia than those non-drinkers (19.4% vs. 30.4%, P < 0.001 in males and 9.5% vs. 20.4%, P = 0.004 in females, respectively). Moreover, male drinkers had higher levels of muscle mass [median (IQR): 7.3 (6.7-7.9) kg/m2 vs. 7.1 (6.5-7.7) kg/m2, P < 0.001] grip strength [median (IQR): 31.1 (26.5-35.0) kg vs. 29.6 (24.8-38.8) kg, P < 0.001], and gait speed [median (IQR): 1.08 (0.98-1.17) m/s vs. 1.05 (0.94-1.15) m/s, P < 0.001] than those non-drinkers, while female drinkers had higher gait speed [median (IQR): 1.02 (0.94-1.11) m/s vs. 0.99 (0.89-1.09) m/s, P = 0.031] than those non-drinkers. Multivariate logistic regression showed that in older adults younger than 85 years, both interim drinking (RR = 0.60; 95%CI = 0.39-0.93; P = 0.021 for males; RR = 0.36; 95%CI = 0.13-0.90; P = 0.035 for females) and daily drinking (RR = 0.78; 95%CI = 0.61-0.99; P = 0.045 for males; RR = 0.34; 95%CI = 0.12-0.96; P = 0.041 for females) were correlated with decreased risk of sarcopenia even after adjustment for confounding factors. However, our dose-response analysis did not show any significant relationship between daily alcohol intake and the risk of sarcopenia as well as the components of sarcopenia. In conclusion, our results indicated that alcohol drinking may not be a risk factor for sarcopenia in the older adults. Further research will help to understand the underlying mechanism of the observed causal relationship.
饮酒和肌肉减少症之间的关系仍然存在争议。本研究的目的是调查老年人饮酒与肌肉减少症的关系。对5244名年龄≥65岁的中国社区老年人进行前瞻性研究。通过阑尾骨骼肌质量指数、握力和步态速度评估骨骼肌减少症。采用定量问卷调查的方式获取饮酒情况。经过4年的随访,我们的研究表明,饮酒者肌肉减少症的发生率低于不饮酒者(男性19.4%比30.4%,P < 0.001;女性9.5%比20.4%,P = 0.004)。此外,男性饮酒者的肌肉质量[中位数(IQR): 7.3 (6.7-7.9) kg/m2 vs. 7.1 (6.5-7.7) kg/m2, P < 0.001]、握力[中位数(IQR): 31.1 (26.5-35.0) kg vs. 29.6 (24.8-38.8) kg, P < 0.001]、步速[中位数(IQR): 1.08 (0.98-1.17) m/s vs. 1.05 (0.94-1.15) m/s, P < 0.001]高于不饮酒者,而女性饮酒者的步速[中位数(IQR): 1.02 (0.94-1.11) m/s vs. 0.99 (0.89-1.09) m/s, P = 0.031]高于不饮酒者。多因素logistic回归显示,在年龄小于85岁的老年人中,中期饮酒(RR = 0.60;95%ci = 0.39-0.93;男性P = 0.021;Rr = 0.36;95%ci = 0.13-0.90;女性P = 0.035)和每日饮酒(RR = 0.78;95%ci = 0.61-0.99;男性P = 0.045;Rr = 0.34;95%ci = 0.12-0.96;P = 0.041(女性)与降低肌肉减少症的风险相关,即使在调整混杂因素后也是如此。然而,我们的剂量反应分析并没有显示每日酒精摄入量与肌肉减少症的风险以及肌肉减少症的组成部分之间有任何显著的关系。总之,我们的结果表明,饮酒可能不是老年人肌肉减少症的危险因素。进一步的研究将有助于理解观察到的因果关系的潜在机制。
{"title":"Alcohol consumption may not be a risk factor for sarcopenia in the older adults.","authors":"En-Hui Mao, Yun-Ling Bu, Qiao-Ling Liu, Jin-Shui Xu, Xiang Lu, Xi-Lan Yang, Wei Gao, Zheng-Kai Shen","doi":"10.3389/ebm.2025.10520","DOIUrl":"10.3389/ebm.2025.10520","url":null,"abstract":"<p><p>The relationship between drinking and sarcopenia remains controversial. The aim of the present study was to investigate the association of alcohol drinking with sarcopenia in the older adults. A prospective study with 5244 Chinese community-dwelling older adults aged ≥65 years was performed. Sarcopenia was assessed by appendicular skeletal muscle mass index, grip strength, and gait speed. A quantitative questionnaire was used to obtain the information of alcohol drinking. After 4-year follow-up, our study showed that drinkers had lower incidence of sarcopenia than those non-drinkers (19.4% vs. 30.4%, <i>P</i> < 0.001 in males and 9.5% vs. 20.4%, <i>P</i> = 0.004 in females, respectively). Moreover, male drinkers had higher levels of muscle mass [median (IQR): 7.3 (6.7-7.9) kg/m<sup>2</sup> vs. 7.1 (6.5-7.7) kg/m<sup>2</sup>, <i>P</i> < 0.001] grip strength [median (IQR): 31.1 (26.5-35.0) kg vs. 29.6 (24.8-38.8) kg, <i>P</i> < 0.001], and gait speed [median (IQR): 1.08 (0.98-1.17) m/s vs. 1.05 (0.94-1.15) m/s, <i>P</i> < 0.001] than those non-drinkers, while female drinkers had higher gait speed [median (IQR): 1.02 (0.94-1.11) m/s vs. 0.99 (0.89-1.09) m/s, <i>P</i> = 0.031] than those non-drinkers. Multivariate logistic regression showed that in older adults younger than 85 years, both interim drinking (RR = 0.60; 95%CI = 0.39-0.93; <i>P</i> = 0.021 for males; RR = 0.36; 95%CI = 0.13-0.90; <i>P</i> = 0.035 for females) and daily drinking (RR = 0.78; 95%CI = 0.61-0.99; <i>P</i> = 0.045 for males; RR = 0.34; 95%CI = 0.12-0.96; <i>P</i> = 0.041 for females) were correlated with decreased risk of sarcopenia even after adjustment for confounding factors. However, our dose-response analysis did not show any significant relationship between daily alcohol intake and the risk of sarcopenia as well as the components of sarcopenia. In conclusion, our results indicated that alcohol drinking may not be a risk factor for sarcopenia in the older adults. Further research will help to understand the underlying mechanism of the observed causal relationship.</p>","PeriodicalId":12163,"journal":{"name":"Experimental Biology and Medicine","volume":"250 ","pages":"10520"},"PeriodicalIF":2.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12160937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144283077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}